Therapeutic and pleiotropic effects of statins in the prevention of cardiovascular disease;Effets thérapeutiques et pléiotropiques des statines dans la prévention primaire et secondaire des maladies cardiovasculaires

Medecine et Hygiene

Volumn 60, Issue 2391, 2002, Pages 967-970

  Mach, François ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEGA 3 FATTY ACID; RESIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG TARGETING; DYSLIPIDEMIA; FEMALE; HUMAN; LIVER TOXICITY; MEDICAL DOCUMENTATION; PATIENT CARE; PLEIOTROPY; PRIMARY PREVENTION; RHABDOMYOLYSIS; RISK MANAGEMENT; SECONDARY PREVENTION; SWITZERLAND;

EID: 0037042393     PISSN: 00256749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study
2. The global burden of disease, 1990-2020
3. Pharmacology of competitive inhibitors of HMG-CoA reductase
4. Drug treatment of lipid disorders
5. Current perspective on statins
6. Anti-atherothrombotic properties of statines: Implications for cardiovascular event reduction
7. Comparison of statins in hypertryglyceridemia
8. High density lipoprotien restores endothelial function in hypercholesteronelmic men
9. Prevention of coronary disease by raising high-density lipoprotein cholesterol?
10. Development of tachyphylaxis among patients taking HMG-CoA reductase inhibitors
11. Molecular basis of acute coronary syndromes
12. Atherosclerosis: The road ahead
13. Coronary plaque disruption
14. L'athérosclérose: Une maladie inflammatoire
15. Statins do more than just lower cholesterol
16. Non-lipid-related effects of statins
17. The evolving role of statins in the management of atherosclerosis
18. Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts
19. Withdrawal of statins increases event rates in patients with acute coronary syndromes
20. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: Report from the program on Surgical Control of the Hyperlipidemias (POSCH)
21. Reduction in incidence of coronary heart disease
22. New evidence for beneficial effects of statins unrelated to lipid lowering
23. Low-density lipoprotein-independent effects of statins
24. Statins inhibit leukocyte recruitment: New evidence for their anti-inflammatory properties
25. Beneficial effects of cholesterol lowering therapy on the coronary endothelium in patients with coronary artery disease
26. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
27. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia
28. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
29. Are statins anti-inflammatory?
30. Long-term effects of pravastatin on plasma concentration of C-reactive protein
31. Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the WOSCOP study
32. Inhibitors of the HMG-CoA reductase and risk of fracture among older women
33. The role of cholesterol in the biosynthesis of beta-amyloid
34. Effect of pravastatin on outcomes after cardiac transplantation
35. Statins as a newly recognized type of immunosuppressor
36. Effects thérapeutiques et pléiotrophiques des statins dans la prévention primaire et secondaire de l'athérosclérose
37. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
38. Inhibiteurs de l'HMG-CoA reductase et interactions médicamenteuses